• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Business/Financial News

Dexcom CEO Jake Leach talks Nutrisense acquisition, type 2 push, next-gen G8

June 9, 2026 By Sean Whooley

Dexcom G7 15-day CGM (1)

Nearly halfway through 2026, the milestones are already stacking up for continuous glucose monitor (CGM) maker Dexcom (Nadsaq:DXCM). President and CEO Jake Leach took over the corner office in January. In the months that have followed, highlights include the unveiling of the next-generation G8 sensor system, the launch of the Flex sensor platform outside the […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: ADA 2026, Dexcom

Glooko launches EHR integration for insulin pumps

June 5, 2026 By Sean Whooley

Glooko Logo

Glooko announced today that it launched its Insulin Pump Settings Electronic Health Record (EHR) integration capability. Palo Alto, California-based Glooko says the first-of-its-kind capability within its latest software release visualizes critical insulin pump configuration data directly into the clinical workflow. The company says that visibility of pump settings provides essential clinical context for clinics caring […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Hospital Care, Patient Monitoring, Technology Tagged With: glooko

Dexcom to acquire wellness tracking company Nutrisense, launch enhanced Stelo app

June 4, 2026 By Sean Whooley

Dexcom CGM lifestyle

Dexcom (Nasdaq:DXCM) announced today that entered into an agreement to acquire Nutrisense and shared plans for upgrades to its Stelo sensor. San Diego-based Dexcom expects its deal to buy Nutrisense for an undisclosed amount in the coming weeks. With the acquisition, the continuous glucose monitor (CGM) maker plans to further expand its ability to support […]

Filed Under: Business/Financial News, Diabetes, Featured, Food & Drug Administration (FDA), Mergers & Acquisitions, Patient Monitoring, Technology Tagged With: ADA 2026, Dexcom

CeQur announces extended wear time, added dosing for mealtime insulin patch pump

June 4, 2026 By Sean Whooley

CeQur Simplicity insulin delivery patch (1)

CeQur announced today that it picked up two recent FDA clearances for its Simplicity mealtime insulin patch pump system. The FDA cleared Simplicity for an extended wear time of up to seven days and gave the green light to a new 1-unit (1U) device. Additionally, Horw, Switzerland-based CeQur plans to share two clinical posters at […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Technology Tagged With: ADA 2026, cequr

Advanced NanoTherapies raises $31M for drug-coated balloon tech

June 3, 2026 By Sean Whooley

Advanced NanoTherapies SirPlux Duo

Advanced NanoTherapies announced that it closed an oversubscribed Series B financing worth more than $31 million. An undisclosed strategic investor, along with S3 Ventures, co-led the round. The T45 Fund and new and existing investors also participated. Funding adds to $4 million raised in 2023. The funds support the company’s therapies for coronary and peripheral […]

Filed Under: Business/Financial News, Cardiovascular, Drug-Device Combinations, Funding Roundup, Vascular Tagged With: Advanced NanoTherapies

Insulet launches enhanced Omnipod 5 algorithm, expands Abbott compatibility

June 3, 2026 By Sean Whooley

Insulet Omnipod 5 in Pool

Insulet (Nasdaq:PODD) announced today that it is rolling out new algorithm enhancements for its Omnipod 5 automated insulin delivery system. The company also expanded its compatibility with Abbott sensors, adding the option of pairing Omnipod 5 with FreeStyle Libre 3 Plus. Acton, Massachusetts-based Insulet won FDA clearance for its algorithm enhancements in December 2025. The […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: abbott, Insulet

MiniMed adds Abbott dual glucose-ketone sensor to portfolio, posts Q4 sales beat

June 3, 2026 By Sean Whooley

Abbott Libre Duo dual glucose-ketone sensor CGM in hand

MiniMed (Nasdaq:MMED) announced today that it expanded its agreement with Abbott (NYSE:ABT) to add more sensors to its portfolio. The company also announced fourth-quarter earnings results in tandem with the new Abbott integration. MiniMed has an existing partnership with Abbott through a collaboration between the companies agreed in 2024. They integrated Instinct, a sensor made by […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Patient Monitoring, Technology, Wall Street Beat Tagged With: abbott, minimed

MyLife integrates MyLoop automated insulin pump with Dexcom G7

June 3, 2026 By Sean Whooley

MyLife Diabetes Care MyLoop AID system

MyLife Diabetes Care, CamDiab and Dexcom today announced the integration of the G7 continuous glucose monitor (CGM) into the MyLoop system. MyLoop (previously MyLife Loop), an automated insulin delivery (AID) system, is powered by the CamAPS FX app. The system already integrated with the previous-generation Dexcom G6, as well as Abbott’s FreeStyle Libre 3 Plus. […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: CamDiab, Dexcom, MyLife Diabetes Care

MyLife takes on manufacturing responsibility for insulin pumps

June 1, 2026 By Sean Whooley

MyLife Diabetes Care MyLife Loop automated insulin delivery system

MyLife Diabetes Care today announced its next steps as an independent diabetes care technology company. Burgdorf, Switzerland-based MyLife says it has now become the legal manufacturer for MyLife products, as of today, June 1, 2026. It plans to introduce products under the new legal manufacturer to the market in a step-by-step process beginning July 1, […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Technology Tagged With: MyLife Diabetes Care

Ascensia launches new insulin pen needles

June 1, 2026 By Sean Whooley

Ascensia Diabetes Care Contour Comfort insulin pen needles

Ascensia Diabetes Care, a PHC Holdings subsidiary, today announced the launch of its Contour Comfort pen needles. The Basel, Switzerland-based company said the launch further strengthens its Contour portfolio with a solution that improves the everyday injection experience. It marks the company’s entry into the pen needle category. Ascensia designed Contour Comfort pen needles to […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations Tagged With: Ascensia Diabetes Care

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Interim pages omitted …
  • Page 195
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS